Assessment of adherence to antituberculosis drug regimen among patients receiving isoniazid, rifampin and pyrazinamide: Kerman, Iran

Authors

  • Khosravi, Ali Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences
  • Sarrafzadeh, Farhad Department of Internal Medicine, School of Medicine, Kerman University of Medical Sciences
  • Sohrevardi, Seyyed Mojtaba Department of Clinical Pharmacy, Herbal Medicine Research Center, School of Pharmacy, Shahid Sadoughi University of Medical Sciences,
Abstract:

Introdution: Among infectious diseases, tuberculosis is one of the leading causes of death killing in nearly 1.5 million people yearly. Considering the importance of patient co-operation in drug therapy and resistance we decided to evaluate the rate of co-operation of tuberculosis infected patients in regard to their use of anti-tuberculosis drugs in Kerman. Methods: This descriptive study was conducted as a sectional and census study and 80 patients succeeded to finalize it. Demographic information was collected through a questionnaire by patients. To carry out the designed test, a urinary sample was taken from each patient and a few drops of each were added to the drug-specific reagents. On the basis of color variation which is special for rifampin, isoniazid and pyrazinamide, we made a decision on the co-operation of the patients. The collected data were analyzed by the the use of SPSS software version 18 and p-value<0.05 was acceptable. To find out the relation between variables, the Chi-square test was applied. Results: The results of this study showed that the total co-operation rate for patients administered with isoniazid was 70%, rifampin 70%, and pirazinamide 68.1%. The quality of adherence to drug orders with age, knowledge of unwanted adverse effects, opium addiction and duration of drug use had a significant relationship (P <0.05); but  with gender, duration of illness, use of another drug, and the presence of another TB infected in the family, no significant difference was observed. Conclusion: We resulted that factors such as age, addiction and lifestyle, duration of treatment and awareness of side effects influence on the co-operation of the patients on drug usage. So that people over 35 years, addict ones, treated for a long time and in the patients with lack of awareness of drug side effects, their adherence to the treatment regimen was lower.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Numerous studies have reported low concentrations of antituberculosis drugs in tuberculosis (TB) patients, but few studies have examined whether low drug concentrations affect TB treatment response. We examined steady-state plasma concentrations of isoniazid, rifampin, and pyrazinamide at 2 h after the administration of drugs (C(2 h)) among 181 patients with pulmonary tuberculosis in Indonesia ...

full text

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide were studied in healthy controls and patients with active pulmonary tuberculosis. A case-control study of 29 controls and 30 cases attending at the Health Center, July, 2004 to December, 2005 was conducted. The body mass index was significantly reduced in cases compared to controls (p < 0.001). The inte...

full text

Antituberculosis Drug-Induced Hepatotoxicity in Iranian Tuberculosis Patients: Role of Isoniazid Metabolic Polymorphism

The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma acetyl-Isoniazid to Isoniazid. The association between hepatotoxicity and the n-acetyltransferas...

full text

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Evaluation of sources of pharmacokinetic variation can facilitate optimization of tuberculosis treatment regimens by identification of avoidable sources of variation and of risk factors for low or high drug concentrations in patients. Our objective was to describe the pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in a cohort of tuberculosis patients established on first-...

full text

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.

The aim of this study was to determine the current incidence of side-effects severe enough to cause intolerance of standard antituberculosis therapy with isoniazid, rifampin and pyrazinamide in patients hospitalized as a result of pulmonary tuberculosis. Five hundred and nineteen patients with proven pulmonary tuberculosis, who initially received standard antituberculosis therapy, were retrospe...

full text

Antituberculosis Drug-Induced Hepatotoxicity in Iranian Tuberculosis Patients: Role of Isoniazid Metabolic Polymorphism

The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma acetyl-Isoniazid to Isoniazid. The association between hepatotoxicity and the n-acetyltransferas...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 27  issue 3

pages  1395- 1404

publication date 2019-07

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023